Furthermore, TRPML1 agonist ML-SA1 reduced LDL-induced amyloidogenesis in the AD brain, while TRPML1 silencing potentiated the detrimental process induced by LDL derived from the peripheral circulation [64]. This evidence concerns the gene MCOLN1 and Alzheimer disease.